SCHEMBL10293241

SCHEMBL10293241

Cc1c(C(=O)NC2CC2)oc2ccc(S(=O)(=O)Nc3nncs3)cc12

nearest known ligand 0.58

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.58
CNR1 P21554 4/20 0.54
CNR2 P34972 4/20 0.54
ALDH1A1 P00352 1/20 0.48
RAB9A P51151 6/20 0.48
NPC1 O15118 5/20 0.48
AKT1 P31749 2/20 0.45
NPSR1 Q6W5P4 2/20 0.42
LMNA P02545 1/20 0.42
MAPT P10636 1/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
TSHR P16473 1/20 0.42
GAA P10253 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10293106 0.85 TDP1 (0.58) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL10293201 0.84 TDP1 (0.59) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL1156370 0.81 TDP1 (0.62) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL10293099 0.81 TDP1 (0.64) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL1156495 0.81 TDP1 (0.64) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL10293169 0.81 TDP1 (0.64) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL8277464 0.79 NPC1 (0.62) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL10293142 0.79 TDP1 (0.59) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL8276806 0.78 TDP1 (0.58) TDP1CNR1CNR2ALDH1A1RAB9A
SCHEMBL1155893 0.78 TDP1 (0.71) TDP1CNR1CNR2ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8211935-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-07-03 US disclosed
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-21 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-7888384-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-02-15 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2009-10-08 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed
US-7569604-B2 Heterocyclic derivatives for modulation of calcium channels VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253682-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C TDP1 4014/4885CNR1 180/4885CNR2 162/4885
US-20110178061-A1 HETEROCYCLIC DERIVATIVES FOR MODULATION OF CALCIUM CHANNELS CACNA1D, ORAI1, CACNA1C TDP1 4014/4885CNR1 180/4885CNR2 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.